Endexx Corp
Endexx Corporation develops and sells hemp-derived products for the health and wellness market under the CBD Unlimited brand in the United States and internationally. The company offers cannabidiol oils, topicals, capsules, snacks, and beverages, as well as equine products for dogs and cats under the PhytoBites brand. It serves medical, biotech, and life science industries. The company was former… Read more
Endexx Corp (EDXC) - Net Assets
Latest net assets as of March 2025: $-32.53 Million USD
Based on the latest financial reports, Endexx Corp (EDXC) has net assets worth $-32.53 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.54 Million) and total liabilities ($34.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-32.53 Million |
| % of Total Assets | -2115.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Endexx Corp - Net Assets Trend (2013–2024)
This chart illustrates how Endexx Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Endexx Corp (2013–2024)
The table below shows the annual net assets of Endexx Corp from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $-21.09 Million | -6.55% |
| 2023-09-30 | $-19.79 Million | -104.16% |
| 2022-09-30 | $-9.69 Million | +2.94% |
| 2021-09-30 | $-9.99 Million | +5.36% |
| 2020-09-30 | $-10.55 Million | -121.79% |
| 2019-09-30 | $-4.76 Million | -100.80% |
| 2018-09-30 | $-2.37 Million | -4.43% |
| 2017-09-30 | $-2.27 Million | +3.41% |
| 2016-09-30 | $-2.35 Million | -986.84% |
| 2015-09-30 | $-216.16K | -152.77% |
| 2014-09-30 | $409.65K | +184.95% |
| 2013-09-30 | $-482.23K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Endexx Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4736893100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.03K | % |
| Other Components | $35.14 Million | % |
| Total Equity | $-19.10 Million | 100.00% |
Endexx Corp Competitors by Market Cap
The table below lists competitors of Endexx Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sasfin
JSE:SFN
|
$457.92K |
|
BANK PEKAO (BP1.SG)
STU:BP1
|
$458.00K |
|
ROSENBAUER INTERNAT - Dusseldorf Stock Exchang
DU:ROI
|
$458.39K |
|
Mednow Inc
PINK:MDNWF
|
$458.45K |
|
Ecoclime Group AB Series B
ST:ECC-B
|
$457.44K |
|
Emailul SA
RO:EMAI
|
$457.27K |
|
Iocaste Ventures Inc.
V:ICY-P
|
$456.85K |
|
Cofix Group Ltd
TA:CFX
|
$456.82K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Endexx Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -17,554,950 to -19,096,800, a change of -1,541,850.
- Net loss of 3,397,330 reduced equity.
- Other comprehensive income increased equity by 50,635.
- Other factors increased equity by 1,804,845.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.40 Million | -17.79% |
| Other Comprehensive Income | $50.63K | +0.27% |
| Other Changes | $1.80 Million | +9.45% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Endexx Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-09-30 | $0.00 | $0.01 | x |
| 2014-09-30 | $0.00 | $0.01 | x |
| 2015-09-30 | $0.00 | $0.01 | x |
| 2016-09-30 | $-0.01 | $0.01 | x |
| 2017-09-30 | $-0.01 | $0.01 | x |
| 2018-09-30 | $-0.01 | $0.01 | x |
| 2019-09-30 | $-0.01 | $0.01 | x |
| 2020-09-30 | $-0.03 | $0.01 | x |
| 2021-09-30 | $-0.02 | $0.01 | x |
| 2022-09-30 | $-0.02 | $0.01 | x |
| 2023-09-30 | $-0.03 | $0.01 | x |
| 2024-09-30 | $-0.04 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Endexx Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -205.20%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-8.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-189.45K |
| 2014 | -99.60% | -1177.89% | 0.02x | 5.25x | $-448.98K |
| 2015 | 0.00% | -926.20% | 0.08x | 0.00x | $-1.15 Million |
| 2016 | 0.00% | -351.82% | 1.01x | 0.00x | $-541.73K |
| 2017 | 0.00% | -159.83% | 0.95x | 0.00x | $-441.82K |
| 2018 | 0.00% | -217.94% | 1.05x | 0.00x | $-1.50 Million |
| 2019 | 0.00% | -760.28% | 0.42x | 0.00x | $-10.91 Million |
| 2020 | 0.00% | -409.01% | 0.66x | 0.00x | $-7.01 Million |
| 2021 | 0.00% | -1046.58% | 0.37x | 0.00x | $-5.81 Million |
| 2022 | 0.00% | -228.98% | 0.16x | 0.00x | $-3.95 Million |
| 2023 | 0.00% | -166.26% | 0.38x | 0.00x | $-4.74 Million |
| 2024 | 0.00% | -205.20% | 0.15x | 0.00x | $-1.49 Million |
Industry Comparison
This section compares Endexx Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Endexx Corp (EDXC) | $-32.53 Million | 0.00% | N/A | $457.48K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |